Table 1 General information on selected BIAs
From: A systematic review of the budget impact analyses for antitumor drugs of lung cancer
First author | Year | Country | Drugs | Research foundation | Population size, characteristics |
|---|---|---|---|---|---|
Carlson [31] | 2011 | US | Erlotinib | Model | 500,000 member US health plan; stage IIIB/IV NSCLC. |
Farsai [39] | 2011 | Thailand | Pemetrexed | Model | Lung cancer patients in the hospital |
Sumitra [40] | 2012 | Thailand | Gefitinib | Model | 100,000 advanced NSCLC patients |
Preeti [32] | 2014 | US | Erlotinib | Model | 500,000 member health plan; with advanced NSCLC |
Lisa [33] | 2016 | US | Ramucirumab + docetaxel | Model | 150,000 patients in hospital; NSCLC Patients Receiving 2nd line Therapy |
Mengyuan [41] | 2016 | China | Gefitinib | Model | 74000 advanced NSCLC patients |
Sumitra [42] | 2017 | Thailand | Crizotinib | Model | 5183 NSCLC in lung cancer patient; aged ≧19 years |
Daniel [34] | 2017 | US | Pembrolizumab | Model | 19601 NSCLC patients with PD-L1 expression ≧ 50% |
Jan [43] | 2017 | Norway | Pembrolizumab | Model | 3035 cases; Patients with advanced NSCLC 2nd line treatment |
Pedro [44] | 2018 | South American countries | Pembrolizumab | RCT | 3043 participants; patients with NSCLC for immunotherapy |
Christopher [35] | 2018 | US | Necitumumab | Model | 100,000 plan participants; msqNSCLC patients receiving first-line chemotherapy; aged≧65 years |
Jonathan [36] | 2018 | US | Afatinib | Model | Health plan for 1,000,000 people; metastatic NSCLC whose tumors have EGFR del19 or L858R mutations initiating first-line treatment; age ≥ 18 years |
Xueyan [45] | 2018 | China | Icotinib | Model | 73,400 patients with advanced NSCLC who were genetically tested and eligible for icotinib in the insured population |
Jie [46] | 2019 | China | Afatinib | Model | 45,554 patients with advanced NSCLC who were positive for EGFR mutation after chemotherapy in the insured population |